Takeda to commercialize ImmunoGen’s Elahere in Japan; Valneva shares safety data for its chikungunya vaccine

Take­da plans to pay Im­muno­Gen $34 mil­lion as part of a deal to de­vel­op and com­mer­cial­ize Im­muno­Gen’s can­cer treat­ment Ela­here in Japan.

Im­muno­Gen re­tains ex­clu­sive pro­duc­tion rights for Ela­here and can al­so get oth­er mile­stone pay­ments and a piece of Ela­here’s net sales in Japan.

Part of the $34 mil­lion could in­clude a mile­stone pay­ment for Im­muno­Gen if Ela­here’s ac­cel­er­at­ed ap­proval in plat­inum-re­sis­tant ovar­i­an can­cer in No­vem­ber is con­vert­ed to a full FDA ap­proval. A con­fir­ma­to­ry tri­al in May showed the drug re­duced the risk of death by 33% com­pared to chemo in pa­tients with ad­vanced ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.